$KITE Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Kite Pharma, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Kite Pharma, Inc.. Get notifications about new insider transactions in Kite Pharma, Inc. for free.
Page: < prev 1 ... 2 3 4 5 6 7 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 19 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 0.70 | 5,500 | 3,850 | 6,499 | 999 to 6.5 K (+550.55 %) |
| Aug 04 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Option Exercise | M | 0.38 | 9,000 | 3,420 | 114,000 | |
| Aug 04 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 74.01 | 690 | 51,067 | 1,017 | 1.7 K to 1 K (-40.42 %) |
| Aug 04 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 73.03 | 1,857 | 135,617 | 1,707 | 3.6 K to 1.7 K (-52.10 %) |
| Aug 04 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 72.33 | 2,784 | 201,367 | 3,564 | 6.3 K to 3.6 K (-43.86 %) |
| Aug 04 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 71.19 | 3,669 | 261,196 | 6,348 | 10 K to 6.3 K (-36.63 %) |
| Aug 04 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Buy | M | 0.38 | 9,000 | 3,420 | 10,017 | 1 K to 10 K (+884.96 %) |
| Aug 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 7,700 | 53,053 | 276,900 | |
| Aug 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 73.87 | 319 | 23,565 | 6,000 | 6.3 K to 6 K (-5.05 %) |
| Aug 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 72.93 | 2,205 | 160,811 | 6,319 | 8.5 K to 6.3 K (-25.87 %) |
| Aug 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 72.29 | 2,276 | 164,532 | 8,524 | 10.8 K to 8.5 K (-21.07 %) |
| Aug 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 71.15 | 2,900 | 206,335 | 10,800 | 13.7 K to 10.8 K (-21.17 %) |
| Aug 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 7,700 | 53,053 | 13,700 | 6 K to 13.7 K (+128.33 %) |
| Jul 28 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Option Exercise | M | 1.35 | 10,000 | 13,500 | 395,394 | |
| Jul 28 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 68.96 | 4,238 | 292,252 | 74,566 | 78.8 K to 74.6 K (-5.38 %) |
| Jul 28 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 68.13 | 5,762 | 392,565 | 78,804 | 84.6 K to 78.8 K (-6.81 %) |
| Jul 28 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Buy | M | 1.35 | 10,000 | 13,500 | 84,566 | 74.6 K to 84.6 K (+13.41 %) |
| Jul 23 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 17.00 | 13,542 | 230,214 | 36,458 | |
| Jul 23 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 0.70 | 8,625 | 6,038 | 124,125 | |
| Jul 23 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 72.92 | 4,925 | 359,131 | 999 | 5.9 K to 999 (-83.14 %) |
| Jul 23 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 72.15 | 8,416 | 607,214 | 5,924 | 14.3 K to 5.9 K (-58.69 %) |
| Jul 23 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 71.22 | 7,395 | 526,672 | 14,340 | 21.7 K to 14.3 K (-34.02 %) |
| Jul 23 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 70.34 | 1,431 | 100,657 | 21,735 | 23.2 K to 21.7 K (-6.18 %) |
| Jul 23 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 17.00 | 13,542 | 230,214 | 23,166 | 9.6 K to 23.2 K (+140.71 %) |
| Jul 23 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 0.70 | 8,625 | 6,038 | 9,624 | 999 to 9.6 K (+863.36 %) |
| Jul 20 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Option Exercise | M | 6.89 | 9,000 | 62,010 | 148,000 | |
| Jul 20 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Sell | S | 73.42 | 100 | 7,342 | 5,218 | 5.3 K to 5.2 K (-1.88 %) |
| Jul 20 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Sell | S | 72.65 | 3,951 | 287,040 | 5,318 | 9.3 K to 5.3 K (-42.63 %) |
| Jul 20 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Sell | S | 71.55 | 3,519 | 251,784 | 9,269 | 12.8 K to 9.3 K (-27.52 %) |
| Jul 20 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Sell | S | 70.92 | 1,024 | 72,622 | 12,788 | 13.8 K to 12.8 K (-7.41 %) |
| Jul 20 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Sell | S | 70.12 | 406 | 28,469 | 13,812 | 14.2 K to 13.8 K (-2.86 %) |
| Jul 20 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Buy | M | 6.89 | 9,000 | 62,010 | 14,218 | 5.2 K to 14.2 K (+172.48 %) |
| Jul 20 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Option Exercise | M | 1.35 | 9,567 | 12,915 | 171,299 | |
| Jul 20 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 73.08 | 793 | 57,952 | 1,695 | 2.5 K to 1.7 K (-31.87 %) |
| Jul 20 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 72.53 | 3,567 | 258,715 | 2,488 | 6.1 K to 2.5 K (-58.91 %) |
| Jul 20 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 71.45 | 4,241 | 303,019 | 6,055 | 10.3 K to 6.1 K (-41.19 %) |
| Jul 20 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 70.54 | 966 | 68,142 | 10,296 | 11.3 K to 10.3 K (-8.58 %) |
| Jul 20 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Buy | M | 1.35 | 9,567 | 12,915 | 11,262 | 1.7 K to 11.3 K (+564.42 %) |
| Jul 02 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Option Exercise | M | 0.38 | 9,000 | 3,420 | 123,000 | |
| Jul 02 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 62.82 | 2,514 | 157,929 | 1,017 | 3.5 K to 1 K (-71.20 %) |
| Jul 02 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 62.06 | 3,177 | 197,165 | 3,531 | 6.7 K to 3.5 K (-47.36 %) |
| Jul 02 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 61.04 | 3,309 | 201,981 | 6,708 | 10 K to 6.7 K (-33.03 %) |
| Jul 02 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Buy | M | 0.38 | 9,000 | 3,420 | 10,017 | 1 K to 10 K (+884.96 %) |
| Jul 02 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 7,700 | 53,053 | 284,600 | |
| Jul 02 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 62.97 | 1,410 | 88,788 | 6,000 | 7.4 K to 6 K (-19.03 %) |
| Jul 02 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 62.31 | 2,896 | 180,450 | 7,410 | 10.3 K to 7.4 K (-28.10 %) |
| Jul 02 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 61.15 | 3,394 | 207,543 | 10,306 | 13.7 K to 10.3 K (-24.77 %) |
| Jul 02 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 7,700 | 53,053 | 13,700 | 6 K to 13.7 K (+128.33 %) |
| Jul 02 2015 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 63.82 | 500 | 31,910 | 1,761,957 | 1.8 M to 1.8 M (-0.03 %) |
| Jul 02 2015 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 63.01 | 358,757 | 22,605,279 | 1,762,457 | 2.1 M to 1.8 M (-16.91 %) |
| Jul 02 2015 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 62.14 | 113,047 | 7,024,741 | 2,121,214 | 2.2 M to 2.1 M (-5.06 %) |
| Jul 02 2015 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | S | 61.22 | 191,798 | 11,741,874 | 2,234,261 | 2.4 M to 2.2 M (-7.91 %) |
| Jul 01 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Option Exercise | M | 1.35 | 10,000 | 13,500 | 405,394 | |
| Jul 01 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 60.78 | 1,200 | 72,936 | 74,566 | 75.8 K to 74.6 K (-1.58 %) |
| Jul 01 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 59.98 | 5,000 | 299,900 | 75,766 | 80.8 K to 75.8 K (-6.19 %) |
| Jul 01 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 58.87 | 3,800 | 223,706 | 80,766 | 84.6 K to 80.8 K (-4.49 %) |
| Jul 01 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Buy | M | 1.35 | 10,000 | 13,500 | 84,566 | 74.6 K to 84.6 K (+13.41 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Option Exercise | M | 6.89 | 9,000 | 62,010 | 157,000 | |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Sell | S | 58.04 | 3,095 | 179,634 | 5,218 | 8.3 K to 5.2 K (-37.23 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Sell | S | 56.88 | 3,295 | 187,420 | 8,313 | 11.6 K to 8.3 K (-28.39 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Sell | S | 55.93 | 2,610 | 145,977 | 11,608 | 14.2 K to 11.6 K (-18.36 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Buy | M | 6.89 | 9,000 | 62,010 | 14,218 | 5.2 K to 14.2 K (+172.48 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Buy | P | 17.00 | 4,000 | 68,000 | 5,218 | 1.2 K to 5.2 K (+328.41 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 7,700 | 53,053 | 292,300 | |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 58.04 | 2,541 | 147,480 | 6,000 | 8.5 K to 6 K (-29.75 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 56.93 | 2,726 | 155,191 | 8,541 | 11.3 K to 8.5 K (-24.19 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 55.93 | 2,433 | 136,078 | 11,267 | 13.7 K to 11.3 K (-17.76 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 7,700 | 53,053 | 13,700 | 6 K to 13.7 K (+128.33 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | P | 17.00 | 4,000 | 68,000 | 6,000 | 2 K to 6 K (+200.00 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Option Exercise | M | 1.35 | 9,567 | 12,915 | 180,866 | |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 58.02 | 3,367 | 195,353 | 1,695 | 5.1 K to 1.7 K (-66.52 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 56.86 | 3,309 | 188,150 | 5,062 | 8.4 K to 5.1 K (-39.53 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 55.92 | 2,891 | 161,665 | 8,371 | 11.3 K to 8.4 K (-25.67 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Buy | M | 1.35 | 9,567 | 12,915 | 11,262 | 1.7 K to 11.3 K (+564.42 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 0.70 | 8,625 | 6,038 | 132,750 | |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 58.05 | 2,703 | 156,909 | 999 | 3.7 K to 999 (-73.01 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 56.93 | 3,345 | 190,431 | 3,702 | 7 K to 3.7 K (-47.47 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 55.94 | 2,577 | 144,157 | 7,047 | 9.6 K to 7 K (-26.78 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 0.70 | 8,625 | 6,038 | 9,624 | 999 to 9.6 K (+863.36 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | DOUMANI ROY | Director | Option Exercise | A | 59.23 | 10,000 | 592,300 | 10,000 | |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Ruchefsky Steven B | Director | Option Exercise | A | 59.23 | 10,000 | 592,300 | 10,000 | |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Peacock Jonathan M | Director | Option Exercise | A | 59.23 | 10,000 | 592,300 | 10,000 | |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Option Exercise | A | 59.23 | 10,000 | 592,300 | 10,000 | |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Kazam Joshua A | Director | Option Exercise | A | 59.23 | 10,000 | 592,300 | 10,000 | |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Option Exercise | A | 59.23 | 10,000 | 592,300 | 10,000 | |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | BONDERMAN DAVID | Director | Option Exercise | A | 59.23 | 10,000 | 592,300 | 10,000 | |
| Jun 03 2015 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | S | 56.08 | 24,070 | 1,349,846 | 0 | 24.1 K to 0 (-100.00 %) |
| Jun 03 2015 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | S | 55.27 | 200,604 | 11,087,383 | 24,070 | 224.7 K to 24.1 K (-89.29 %) |
| Jun 03 2015 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | S | 57.38 | 7,800 | 447,564 | 224,674 | 232.5 K to 224.7 K (-3.36 %) |
| Jun 03 2015 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | S | 56.44 | 3,754 | 211,876 | 232,474 | 236.2 K to 232.5 K (-1.59 %) |
| Jun 03 2015 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | S | 55.05 | 69,206 | 3,809,790 | 236,228 | 305.4 K to 236.2 K (-22.66 %) |
| Jun 03 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Option Exercise | M | 0.38 | 9,000 | 3,420 | 132,000 | |
| Jun 03 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 57.36 | 190 | 10,898 | 1,017 | 1.2 K to 1 K (-15.74 %) |
| Jun 03 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 54.76 | 4,559 | 249,651 | 1,207 | 5.8 K to 1.2 K (-79.07 %) |
| Jun 03 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 54.31 | 4,251 | 230,872 | 5,766 | 10 K to 5.8 K (-42.44 %) |
| Jun 03 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Buy | M | 0.38 | 9,000 | 3,420 | 10,017 | 1 K to 10 K (+884.96 %) |
| May 29 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Option Exercise | M | 1.35 | 10,000 | 13,500 | 415,394 | |
| May 29 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 51.16 | 100 | 5,116 | 74,566 | 74.7 K to 74.6 K (-0.13 %) |
| May 29 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 51.11 | 100 | 5,111 | 74,666 | 74.8 K to 74.7 K (-0.13 %) |
| May 29 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 50.58 | 9,800 | 495,707 | 74,766 | 84.6 K to 74.8 K (-11.59 %) |
| May 29 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Buy | M | 1.35 | 10,000 | 13,500 | 84,566 | 74.6 K to 84.6 K (+13.41 %) |
| May 19 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 0.70 | 8,625 | 6,038 | 141,375 | |
| May 19 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 52.22 | 130 | 6,789 | 999 | 1.1 K to 999 (-11.51 %) |
| May 19 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 51.59 | 1,674 | 86,362 | 1,129 | 2.8 K to 1.1 K (-59.72 %) |
| May 19 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 50.42 | 2,330 | 117,479 | 2,803 | 5.1 K to 2.8 K (-45.39 %) |
| May 19 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 49.45 | 4,491 | 222,080 | 5,133 | 9.6 K to 5.1 K (-46.66 %) |
| May 19 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 0.70 | 8,625 | 6,038 | 9,624 | 999 to 9.6 K (+863.36 %) |
| May 19 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Option Exercise | M | 6.89 | 9,000 | 62,010 | 166,000 | |
| May 19 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Sell | S | 52.21 | 128 | 6,683 | 1,218 | 1.3 K to 1.2 K (-9.51 %) |
| May 19 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Sell | S | 51.57 | 1,528 | 78,799 | 1,346 | 2.9 K to 1.3 K (-53.17 %) |
| May 19 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Sell | S | 50.49 | 2,638 | 133,193 | 2,874 | 5.5 K to 2.9 K (-47.86 %) |
| May 19 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Sell | S | 49.44 | 4,706 | 232,665 | 5,512 | 10.2 K to 5.5 K (-46.06 %) |
| May 19 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Buy | M | 6.89 | 9,000 | 62,010 | 10,218 | 1.2 K to 10.2 K (+738.92 %) |
| May 19 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Option Exercise | M | 1.35 | 9,567 | 12,915 | 190,433 | |
| May 19 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 52.21 | 30 | 1,566 | 1,695 | 1.7 K to 1.7 K (-1.74 %) |
| May 19 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 51.63 | 1,813 | 93,605 | 1,725 | 3.5 K to 1.7 K (-51.24 %) |
| May 19 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 50.49 | 2,538 | 128,144 | 3,538 | 6.1 K to 3.5 K (-41.77 %) |
| May 19 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 49.47 | 5,186 | 256,551 | 6,076 | 11.3 K to 6.1 K (-46.05 %) |
| May 19 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Buy | M | 1.35 | 9,567 | 12,915 | 11,262 | 1.7 K to 11.3 K (+564.42 %) |
| May 05 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Option Exercise | M | 0.38 | 9,000 | 3,420 | 141,000 | |
| May 05 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 51.97 | 1,228 | 63,819 | 1,017 | 2.2 K to 1 K (-54.70 %) |
| May 05 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 51.00 | 3,616 | 184,416 | 2,245 | 5.9 K to 2.2 K (-61.70 %) |
| May 05 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 50.10 | 4,156 | 208,216 | 5,861 | 10 K to 5.9 K (-41.49 %) |
| May 05 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Buy | M | 0.38 | 9,000 | 3,420 | 10,017 | 1 K to 10 K (+884.96 %) |
| Apr 29 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 59.76 | 10,000 | 597,624 | 64,566 | 74.6 K to 64.6 K (-13.41 %) |
| Mar 31 2015 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | S | 59.91 | 25,560 | 1,531,404 | 43,604 | 69.2 K to 43.6 K (-36.96 %) |
| Mar 31 2015 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | S | 59.91 | 23,349 | 1,398,934 | 112,714 | 136.1 K to 112.7 K (-17.16 %) |
| Mar 31 2015 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | S | 59.91 | 66,948 | 4,011,129 | 149,116 | 216.1 K to 149.1 K (-30.99 %) |
| Mar 31 2015 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | S | 61.24 | 50,000 | 3,062,050 | 70,000 | 120 K to 70 K (-41.67 %) |
| Mar 31 2015 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | S | 61.24 | 13,937 | 853,516 | 136,063 | 150 K to 136.1 K (-9.29 %) |
| Mar 31 2015 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | S | 61.24 | 13,936 | 853,455 | 216,064 | 230 K to 216.1 K (-6.06 %) |
| Dec 30 2014 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Option Exercise | A | 51.96 | 16,100 | 836,556 | 16,100 | |
| Dec 30 2014 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | A | 51.96 | 75,000 | 3,897,000 | 75,000 | |
| Dec 30 2014 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Option Exercise | A | 51.96 | 75,000 | 3,897,000 | 75,000 | |
| Dec 30 2014 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Option Exercise | A | 51.96 | 139,200 | 7,232,832 | 139,200 | |
| Aug 01 2014 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Option Exercise | C | 0.00 | 539,636 | 0 | 0 | |
| Aug 01 2014 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Option Exercise | C | 0.00 | 396,791 | 0 | 0 | |
| Aug 01 2014 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Option Exercise | C | 0.00 | 428,534 | 0 | 0 | |
| Aug 01 2014 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Option Exercise | C | 0.00 | 158,716 | 0 | 0 | |
| Aug 01 2014 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Buy | C | 0.00 | 430,190 | 0 | 430,190 | 0 to 430.2 K |
| Aug 01 2014 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Buy | C | 0.00 | 159,329 | 0 | 159,329 | 0 to 159.3 K |
| Aug 01 2014 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Buy | C | 0.00 | 541,722 | 0 | 2,275,472 | 1.7 M to 2.3 M (+31.25 %) |
| Aug 01 2014 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Buy | C | 0.00 | 398,324 | 0 | 2,138,324 | 1.7 M to 2.1 M (+22.89 %) |
| Jun 27 2014 | KITE | Kite Pharma, Inc. | Ruchefsky Steven B | Director | Option Exercise | C | 0.00 | 1,885,551 | 0 | 0 | |
| Jun 27 2014 | KITE | Kite Pharma, Inc. | Ruchefsky Steven B | Director | Buy | C | 0.00 | 1,892,840 | 0 | 1,892,840 | 0 to 1.9 M |
| Jun 27 2014 | KITE | Kite Pharma, Inc. | Peacock Jonathan M | Director | Buy | J | 15.30 | 66,014 | 1,010,014 | 66,014 | 0 to 66 K |
| Jun 27 2014 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 313,531 | 0 | 0 | |
| Jun 27 2014 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 807,681 | 0 | 0 | |
| Jun 27 2014 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 1,072,245 | 0 | 0 | |
| Jun 27 2014 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Buy | C | 0.00 | 314,743 | 0 | 314,743 | 0 to 314.7 K |